SEQSTER PDM Inc. and Boston University researchers, led by Dr. Rhoda Au, have partnered to develop an innovative early Alzheimer’s screening tool. Dr. Au, a leading expert in digital health, will use SEQSTER’s 1-Click Records platform to collect longitudinal health data that will inform the development of a risk-assessment AI tool.
SEQSTER’s platform simplifies data retrieval from electronic health records, enabling researchers to quickly access a patient’s medical history. This comprehensive data will provide valuable insights into the progression of Alzheimer’s, helping identify individuals at high risk for developing the disease.
Dr. Au’s team will also link the health data to blood-based biomarkers and cognitive assessments. By combining these data sources, they aim to develop an early-stage screening tool that can detect subtle symptoms or increased risk for Alzheimer’s.
The project is made possible by the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize, which recognizes Dr. Au’s groundbreaking work in digital health. Her research holds great promise for providing early diagnosis and intervention for Alzheimer’s, which can significantly impact its progression.
SEQSTER’s 1-Click Records platform empowers patients to control their medical data while accelerating scientific progress. Participants can opt in to contribute their data, promoting wider participation in the study and advancing research efforts.
This collaboration represents a significant step towards addressing the challenges of early Alzheimer’s detection. By leveraging digital health technology and longitudinal data, researchers aim to develop tools that can improve patient outcomes and advance the understanding of this devastating disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
